# Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

> **NCT00373360** · PHASE4 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** treprostinil sodium

## Key facts

- **NCT ID:** NCT00373360
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373360, "Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00373360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*